Drug intelligence / Profile preview

CPT-053

Development stage: Preclinical
Lead developer: Mercaptor Discoveries
Modality: Small Molecules
Administration: Oral

Overview

CPT-053 is a preclinical small molecule multi-kinase inhibitor developed by Mercaptor Discoveries for the treatment of Alzheimer's disease and other tauopathies. The compound is designed to target Cyclin-dependent kinase 1 (CDK1), Cyclin-dependent kinase 5 (CDK5), and Glycogen synthase kinase 3 beta (GSK3B). These kinases are key mediators of tau protein hyperphosphorylation, a process that leads to the formation of neurofibrillary tangles and neurodegeneration. By inhibiting these targets, CPT-053 aims to reduce the pathological accumulation of tau and preserve neuronal function.

Other names: CPT-053CPT053CPT 053

Targets

CDK5 (Cyclin-dependent kinase 5)GSK3 (Glycogen synthase kinase 3 beta)CDK1 (Cyclin-dependent kinase 1)

Beyond the preview

Go deeper on CPT-053.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPT-053.

Explore the full profile